C4 Therapeutics (CCCC) Cash from Investing Activities (QoQ) (2020 - 2026)
Analysis
C4 Therapeutics (CCCC) Cash from Investing Activities (QoQ) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | C4 Therapeutics | 489.46 Mn | 235.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -191.72% |
| Mar 31, 2026 | 120.01% |
| Dec 31, 2025 | -2,075.84% |
| Sep 30, 2025 | -89.50% |
| Jun 30, 2025 | 33.63% |
| Mar 31, 2025 | 113.06% |
| Dec 31, 2024 | 8,338.27% |
| Sep 30, 2024 | 101.38% |
| Jun 30, 2024 | 78.08% |
| Mar 31, 2024 | -267.15% |
| Dec 31, 2023 | -44.66% |
| Sep 30, 2023 | 281.07% |
| Jun 30, 2023 | -71.70% |
| Mar 31, 2023 | 476.59% |
| Dec 31, 2022 | -53.38% |
| Sep 30, 2022 | -40.07% |
| Jun 30, 2022 | 929.87% |
| Mar 31, 2022 | 93.26% |
| Dec 31, 2021 | 40.96% |
| Sep 30, 2021 | -410.25% |